PCS
ABBV icon

Personal CFO Solutions’s AbbVie ABBV Stock Holding History

Personal CFO Solutions’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.88M Buy
7,480
+1,626
+28% +$350K 0.27% 64
2026
Q1 		$1.27M Sell
5,854
-568
-9% -$126K 0.18% 99
2025
Q4 		$1.47M Buy
6,422
+141
+2% +$32.1K 0.23% 72
2025
Q3 		$1.45M Sell
6,281
-185
-3% -$37.7K 0.26% 73
2025
Q2 		$1.2M Sell
6,466
-881
-12% -$164K 0.22% 87
2025
Q1 		$1.54M Sell
7,347
-171
-2% -$33.2K 0.31% 64
2024
Q4 		$1.34M Sell
7,518
-3,797
-34% -$698K 0.26% 72
2024
Q3 		$2.23M Sell
11,315
-62
-0.5% -$11.6K 0.31% 63
2024
Q2 		$1.95M Buy
11,377
+48
+0.4% +$7.95K 0.3% 64
2024
Q1 		$2.06M Buy
11,329
+302
+3% +$52K 0.32% 61
2023
Q4 		$1.71M Buy
11,027
+4,738
+75% +$691K 0.3% 63
2023
Q3 		$938K Buy
6,289
+485
+8% +$71.2K 0.19% 105
2023
Q2 		$782K Sell
5,804
-98
-2% -$14.4K 0.16% 127
2023
Q1 		$941K Buy
5,902
+319
+6% +$48.8K 0.19% 97
2022
Q4 		$902K Buy
5,583
+413
+8% +$63.3K 0.19% 101
2022
Q3 		$694K Buy
5,170
+147
+3% +$21.1K 0.17% 113
2022
Q2 		$769K Buy
5,023
+216
+4% +$33K 0.18% 98
2022
Q1 		$779K Buy
4,807
+636
+15% +$92.4K 0.15% 129
2021
Q4 		$565K Sell
4,171
-1,340
-24% -$158K 0.11% 180
2021
Q3 		$595K Buy
5,511
+1,553
+39% +$177K 0.12% 163
2021
Q2 		$446K Buy
3,958
+40
+1% +$4.5K 0.09% 206
2021
Q1 		$424K Sell
3,918
-489
-11% -$52.3K 0.09% 203
2020
Q4 		$472K Sell
4,407
-166
-4% -$16K 0.12% 171
2020
Q3 		$0 Buy
4,573
+334
+8% +$31.4K ﹤0.01% 135
2020
Q2 		$416K Sell
4,239
-1,562
-27% -$138K 0.12% 158
2020
Q1 		$442K Buy
5,801
+3,035
+110% +$259K 0.16% 135
2019
Q4 		$245K Hold
2,766
– – 0.07% 269
2019
Q3 		$209K Buy
+2,766
New +$190K 0.08% 262

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Personal CFO Solutions's ABBV Position: Q2 2026 in Review

Personal CFO Solutions increased its AbbVie (ABBV) stake by 28% in Q2 2026, buying an estimated $350K and bringing the position to 7,480 shares worth $1.88M. The position accounts for 0.27% of the portfolio, ranked #64.

Personal CFO Solutions first reported a position in ABBV in Q3 2019 and has held it in 28 quarters since. The position peaked at $2.23M in Q3 2024. 4,214 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Personal CFO Solutions held 7,480 shares of AbbVie worth $1.88M as of Q2 2026.
  • Personal CFO Solutions bought 1,626 AbbVie shares in Q2 2026, an estimated $350K.
  • AbbVie made up 0.27% of Personal CFO Solutions's portfolio in Q2 2026, its #64 holding.
  • Personal CFO Solutions first reported a position in AbbVie in Q3 2019 and has held it in 28 quarters since.
  • Personal CFO Solutions's AbbVie position peaked at $2.23M in Q3 2024.
  • 4,214 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Personal CFO Solutions's 13F filing for Q2 2026, filed 7 Aug 2026.